Author: [email protected]

Unicycive Therapeutics (UNCY) – NDA Resubmission Accepted For FDA Review

Posted on by [email protected]


Thursday, October 22, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

OLC Resubmission Given March 25, 2027 PDUFA Date. Unicycive announced that the FDA has accepted its NDA (New Drug Application) resubmission for OLC (oxylanthanum carbonate) for review. This follows the 30-day period after resubmission in which the FDA determined that it was sufficiently complete for review. The application received a PDUFA (Prescription Drug User Fee Act) date of March 25, 2027. This is the date the FDA must respond to the application by statute and aligns with the TDAPA program deadlines.

The NDA Contains Data From A New Manufacturing Partner. As we had expected, the resubmission was classified as Class 2 and received a six-month review. The CMC (Chemistry, Manufacturing, and Controls) section includes product manufacturing data from a new third-party manufacturing partner. The FDA inspected this manufacturer’s plant in March 2024 and gave a “No Action Indicated” status, the equivalent of a passing grade.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SKYX Platforms (SKYX) – Proof of Concept

Posted on by [email protected]


Thursday, October 22, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Proof. It didn’t take long for SKYX Platforms and new subsidiary Deako to supply proof of concept on one of the key elements of the merger: i.e., cross-selling. Yesterday, SKYX announced that it will supply over 80,000 units of its advanced technologies to over 1,000 homes for Maronda Homes. We believe this announcement will be the first of many.

Details. The Company expects to deliver over 80,000 units of its advanced plug-and-play and smart home technologies to over 1,000 Maronda Homes residences in several states, including Ohio, Georgia, Maryland, and Pennsylvania. If the contract is similar to the $50/unit revenue previously disclosed, the contract would represent some $4 million in revenue.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

US Jobless Claims Fall to 194,000 Near 57-Year Low as Fed Faces Interest Rate Decision

Posted on by [email protected]

New applications for unemployment benefits in the United States fell to one of their lowest levels in nearly six decades, offering fresh evidence that American businesses are holding onto workers despite slower hiring, elevated borrowing costs, and persistent inflation concerns.

According to data released Thursday by the Labor Department, initial jobless claims declined by 6,000 to a seasonally adjusted 194,000 for the week ending October 17. The figure came in below economists’ expectations of 200,000 and marked the sixth consecutive week that claims remained at or below that level.

The latest reading approaches the 189,000 claims recorded in July, the lowest level since 1969. The four-week moving average, which helps smooth weekly fluctuations, declined by 1,000 to 197,750, reinforcing signs that layoffs remain historically low.

The report provides a potentially reassuring signal for investors concerned about the strength of the U.S. economy. Despite higher energy prices, trade uncertainty, and elevated interest rates, employers have largely avoided widespread layoffs.

However, the labor market presents a more complicated picture beneath the headline numbers.

While businesses are retaining existing employees, many remain cautious about expanding their workforces. Economists have characterized the current environment as a “low-hire, low-fire” labor market, where job security remains relatively strong but opportunities for unemployed workers are more limited.

That distinction was evident in continuing unemployment claims, which measure the number of Americans receiving benefits after their initial week. Continuing claims increased by 25,000 to approximately 1.73 million for the week ending October 10.

The increase suggests that some unemployed Americans may be taking longer to find new positions, even as the overall pace of layoffs remains subdued.

Recent employment data further illustrates the uneven recovery in hiring. U.S. employers added just 29,000 jobs in September, following a stronger gain of 133,000 in August. The unemployment rate stood at 4.2%, indicating that the labor market remains relatively stable despite slower job creation.

For Wall Street, the latest unemployment figures arrive at a critical moment for Federal Reserve monetary policy.

The central bank raised its benchmark interest rate by a quarter percentage point in September, bringing the target range to 3.75%–4.00%. Policymakers continue balancing the need to contain inflation against the risk that restrictive borrowing costs could eventually weaken economic activity.

Higher energy prices linked to the conflict involving Iran have complicated that calculation by increasing inflationary pressure on businesses and consumers.

Historically low unemployment claims could give the Federal Reserve additional flexibility to maintain elevated interest rates while monitoring inflation. Economists generally expect policymakers to leave rates unchanged at their upcoming meeting, although another increase remains possible later this year.

The implications extend across financial markets. Interest-rate expectations influence Treasury yields, mortgage costs, corporate borrowing, and equity valuations, particularly among growth-oriented technology companies.

Small-cap companies can also be sensitive to changes in financing conditions because many rely more heavily on external capital to support expansion, research, and operations.

For investors, the latest report offers encouraging evidence that the U.S. economy continues to avoid widespread job losses. Nevertheless, the combination of limited hiring, persistent inflation risks, and higher borrowing costs leaves important questions about the sustainability of economic growth.

With the Federal Reserve’s next policy decision approaching, investors will closely monitor upcoming inflation and employment reports for clues about the direction of interest rates through the remainder of 2026.

Anthropic IPO Could Target $2 Trillion Valuation as AI Giant Prepares Public Filing

Posted on by [email protected]

Anthropic, the artificial intelligence company behind the Claude chatbot, could publicly file its initial public offering prospectus as early as Friday, October 23, setting the stage for what could become one of the largest stock market debuts in history. The anticipated filing comes as investors increasingly question whether the explosive growth of artificial intelligence can justify the industry’s enormous infrastructure spending and soaring valuations.

According to Yahoo Finance, which cited three people familiar with the company’s plans, Anthropic is preparing to make its S-1 registration statement publicly available following a confidential submission to the Securities and Exchange Commission in June. The filing would represent a significant step toward a potential November IPO, although the company has not confirmed the timing or final offering terms.

Wall Street has reportedly discussed a valuation approaching $2 trillion, with the offering potentially raising as much as $100 billion. If achieved, those figures would make Anthropic’s debut a defining moment for the AI investment boom and provide public-market investors with direct exposure to one of the industry’s leading developers of advanced artificial intelligence models.

Founded in 2021 by former OpenAI researchers, including CEO Dario Amodei and President Daniela Amodei, Anthropic has emerged as a major competitor in generative AI. Its Claude family of models powers enterprise applications, coding tools, and workplace automation, positioning the company to benefit from growing corporate demand for AI-powered productivity solutions.

Anthropic’s revenue growth has been extraordinary. According to financial information reported by The Wall Street Journal, the company generated approximately $16.3 billion in revenue during the first six months of 2026. Revenue reportedly accelerated further during the third quarter, reflecting rapid adoption of its products among business customers.

However, that growth has come with substantial financial costs. Reports indicate Anthropic recorded a net loss exceeding $80 billion during the first half of 2026, although much of that figure was attributed to accounting charges associated with financing arrangements rather than direct operating expenses.

The company also faces enormous computing requirements. Training and operating advanced AI models requires extensive access to specialized chips, data centers, and cloud infrastructure. Anthropic maintains major relationships with technology giants including Amazon and Alphabet’s Google, while competing for computing resources in an increasingly capital-intensive industry.

Those spending requirements are becoming a central concern for investors. AI infrastructure companies have experienced heightened volatility in recent weeks as Wall Street evaluates whether future revenue growth will be sufficient to support rising debt levels, expensive computing contracts, and aggressive expansion plans.

The potential Anthropic IPO could arrive during a period of increasing selectivity in the public markets. Recent weakness in AI-related stocks and disappointing technology IPO performances suggest investors are becoming more cautious about companies carrying ambitious valuations without established profitability.

For investors, Anthropic’s public prospectus would provide a more detailed view of the company’s financial performance, operating costs, customer concentration, and long-term capital commitments. Those disclosures could help establish new valuation benchmarks for the broader artificial intelligence sector, including competitors such as OpenAI.

The offering could also influence other technology companies considering public listings. A successful debut might encourage additional AI businesses to enter the market, while weaker demand could signal that investors are becoming less willing to finance rapid expansion at premium valuations.

Although Anthropic has not announced an official IPO date, share price, or stock ticker, the expected public filing represents a major development for the technology industry. As artificial intelligence companies transition from private funding toward public ownership, investors will increasingly demand evidence that extraordinary revenue growth can translate into sustainable profitability.

Release – Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027

Posted on by [email protected]

October 21, 2026 7:05am EDT

Primary Logo

MOUNTAIN VIEW, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The NDA was resubmitted following a Complete Response Letter (CRL) received in June 2026. The FDA has deemed the OLC resubmission a Class II with a six-month review period from the resubmission date, and set a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027.

“We are pleased that the FDA has accepted the resubmission of our NDA for OLC and assigned a PDUFA date,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “This resubmission includes CMC data from a new third-party drug product manufacturing vendor. The new vendor’s facility was last inspected by the FDA in March 2024 and received ‘No Action Indicated’ status. We hope to continue working with the FDA toward potential approval of this important medication to patients with CKD on dialysis who need additional treatment options for managing hyperphosphatemia.”

The Company does not know whether the FDA will decide to conduct a pre-approval inspection of the new third-party DP vendor. Additionally, if the original third-party manufacturing vendor is inspected in the near term and finds that its facility complies with current Good Manufacturing Practice (cGMP), the Company plans to seek FDA alignment on a shorter approval timeline.

The Company resubmitted the NDA following the second CRL, which cited deficiencies previously identified at the original third-party manufacturer of the drug product, which the FDA had not been able to re-inspect during the prior submission review.

The timing and outcome of any FDA inspection of the original third-party vendor will be determined solely by the FDA.

The NDA is supported by data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies, as well as CMC data. The FDA did not raise any concerns regarding OLC’s preclinical or clinical data, including safety data, included in the original NDA submission.

About Oxylanthanum Carbonate
OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden. Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035.

About Hyperphosphatemia
Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.1 Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.

1Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145.

About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Forward-looking statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; Unicycive’s clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; Unicycive’s dependence on third parties for manufacturing; the possibility that FDA may require inspection of any vendor prior to approval, which could delay or prevent approval of its NDA; the risk that the inspection of the original or new third-party manufacturing vendor may not occur within a timeframe that benefits its regulatory timeline, or may result in adverse findings; risks related to business interruptions, which could seriously harm its financial condition and increase its costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of its products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contacts:
Kevin Gardner
LifeSci Advisors
[email protected]

Media Contact:
Unicycive Therapeutics
[email protected] 

SOURCE: Unicycive Therapeutics, Inc.

Release – BODi Launches INSANITY “Liquid Shock” Energy Drink Designed For Sharper Focus, Improved Reaction Time, Physical Performance and a Huge Jolt of Energy

Posted on by [email protected]

October 21, 2026

Formulated to help unlock extreme mental and physical performance, taking you from fatigued to a colossal jolt of energy with sharper focus, zero sugar and just five calories per can

EL SEGUNDO, Calif.–(BUSINESS WIRE)– BODi (NASDAQ: BODI), the proactive wellness company delivering nutrition, supplements and proven fitness programs that help people take control of their health inside and out, today announced the launch of INSANITY Liquid Shock Energy Drink, a zero-sugar, ready-to-drink energy beverage designed to fuel demanding days when ordinary energy isn’t enough. From intense workouts to extreme challenges and long shifts, INSANITY Liquid Shock Energy Drink delivers sustained energy and sharper focus when it matters most.

Formulated to help unlock extreme mental and physical performance, INSANITY Liquid Shock Energy Drinks take you from fatigued to a colossal jolt of energy with sharper focus, zero sugar and just five calories per can.

Inspired by the unrivaled intensity of BODi’s iconic INSANITY training series that millions of users have done over the last 17 years, this drink brings that same relentless intensity to every sip. INSANITY Liquid Shock Energy combines 300 mg of caffeine with TeaCrine® and Dynamine® in a triple-energy formula leveraging these plant-derived stimulant alkaloids for energy and focus. The result is a powerful energy experience that also features a blend of nootropic and performance ingredients designed to support sharper focus, faster reaction time and physical performance, delivering a major jolt of sustained energy.

“Our INSANITY fitness programs challenge people to achieve extraordinary physical and mental results,” said Carl Daikeler, Co-Founder and CEO of BODi. “We wanted an energy drink to match that next-level intensity, and this new INSANITY Liquid Shock Energy Drink delivers. Formulated to go far beyond caffeine alone and other energy drinks, INSANITY Liquid Shock provides an incredible range of performance benefits in a single serve can. We’ve taken the essence of our world-famous INSANITY fitness programs and formulated a powerful energy drink designed for high-intensity achievers, athletes, students, and gamers.”

Five Benefits. One Can. Four Flavors.

INSANITY Liquid Shock Energy Drink goes beyond energy alone, combining caffeine, nootropic and performance ingredients to support the demands of the body and mind.

Available in four unhinged flavors, including Nuclear Sherbet, Off Your Rocket, Radioactive Sour Apple, and Sourmelon Panic, the INSANITY Liquid Shock Energy Drink delivers:

  • A Colossal Jolt: Triple INSANITY energy – 300 mg of caffeine combined with TeaCrine ® and Dynamine ®.
  • Sharper Focus: Alpha-GPC, L-Tyrosine and caffeine to support sharper focus.
  • Reaction Time Support: A nootropic-focused formula to support mental sharpness and response.
  • Physical Performance: L-Citrulline, Betaine, Taurine and caffeine to support physical output.
  • Zero Sugar: Just five calories per can.

Expanding INSANITY and BODi’s Performance Nutrition Portfolio

On November 12, BODi will further expand the INSANITY brand into performance nutrition with the launch of INSANITY Pre-Workout Powder, timed to coincide with the debut of INSANITY: Unhinged, the all-new fitness program featuring three-time HYROX World Champion Hunter McIntyre, launching exclusively on BODi.

Featuring 360 mg of caffeine, TeaCrine®, Dynamine® and performance-focused ingredients, INSANITY Pre-Workout Powder is designed to support energy, endurance, focus, strength and pump for those who push to their limits and still wake up hungry for more.

The INSANITY Liquid Shock Energy Drink and INSANITY Pre-Workout Powder extend the brand into performance nutrition, supporting BODi’s broader portfolio alongside Shakeology, the P90X Supplement System and P90X Energy Drinks.

INSANITY Liquid Shock Energy is available now on BODi.com in a 12-pack case for $29.99which comes to just $2.50 per can. For a limited time, anyone who buys one case can get a second case 50% off. The product will soon be available on Amazon and at other retailers.

Together, these launches reflect BODi’s continued focus on nutrition and performance, extending its iconic fitness franchises into complementary products that support consumers beyond the workout.

To learn more and discover BODi’s entire performance nutrition portfolio, go to: BODi.com.

About BODi and The Beachbody Company

BODi is a proactive wellness company delivering nutrition, supplements, and proven fitness programs that help people take control of their health inside and out. With nearly three decades of experience, BODi, formerly Beachbody, has evolved from a leader in home fitness into a comprehensive health and fitness ecosystem designed to help people achieve their goals and lead healthier, more fulfilling lives. Anchored by science-backed nutrition solutions like Shakeology and supported by its portfolio of proven fitness and habit-building programs, including P90X and INSANITY, BODi is creating a more accessible and effective path to long-term health.

Since its inception, BODi has supported more than 30 million customers in achieving lasting results. The company continues to innovate across nutrition and digital fitness to deliver simple, proven solutions for modern lifestyles.

To subscribe and shop, visit BODi.com. For company and investor information, please visit TheBeachbodyCompany.com.

Media Relations:
[email protected]

Investor Relations:
[email protected]

Source: BODi

Release – Cardiff Oncology Receives FDA Orphan Drug Designation for Onvansertib in Chronic Myelomonocytic Leukemia

Posted on by [email protected]

October 21, 2026

PDF Version

SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia (CMML).

“CMML remains a difficult-to-treat hematologic malignancy with limited treatment options for patients, and 40-50% of myeloproliferative CMML1 patients harbor RAS-pathway mutations, which are associated with more aggressive disease,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Receiving Orphan Drug Designation for onvansertib in CMML further validates the therapeutic potential of PLK1 inhibition in cancers with significant unmet need and adds to the growing body of evidence supporting this mechanism across both solid tumors and hematologic malignancies. We believe this designation highlights the broader clinical opportunity for onvansertib as a monotherapy as we continue advancing therapies for patients across cancers where new therapeutic approaches are urgently needed.”

Onvansertib is being evaluated in both company-sponsored and investigator-initiated clinical studies, including a Phase 1 investigator-initiated study in relapsed/refractory CMML. As presented at the 2025 American Society of Hematology (ASH) Annual Meeting, onvansertib was relatively well-tolerated as a monotherapy and demonstrated preliminary efficacy in approximately 40% of myeloproliferative CMML patients in the dose ranging trial. The responses included three patients experiencing clinical benefits (38%), with one each of the following: a 100% platelet response, normalization of White Blood Cells, WBC (baseline WBC count > 50 x 109/L), and spleen response. Additionally, one patient (12.5%) had optimal marrow response with bone marrow blast reduction from 8% to 2% facilitating for allogeneic hematopoietic stem transplant and 3 patients experienced stable disease (38%).

Orphan Drug Designation is granted by the FDA to support the development of therapies intended to treat rare diseases or conditions affecting fewer than 200,000 people in the United States. Benefits of the designation may include tax credits for qualified clinical trials, exemption from certain FDA user fees, and up to seven years of market exclusivity upon regulatory approval. Orphan Drug Designation does not alter the standard regulatory requirements or approval process.

About Onvansertib
Onvansertib is a highly specific, oral PLK1 inhibitor advancing toward a registrational trial in first-line RAS-mutated metastatic colorectal cancer (mCRC). In a randomized Phase 2 trial, onvansertib in combination with FOLFIRI/bevacizumab (first-line standard-of-care) demonstrated dose-dependent improvements in overall response rate and progression-free survival compared to standard-of-care alone, building on findings from a prior Phase 2 trial in second-line RAS-mutated mCRC. Based on these results, the Company has selected the 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab as the regimen to advance into the planned registrational trial in first-line patients with RAS-mutated mCRC.

Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML).

About Chronic Myelomonocytic Leukemia
Chronic myelomonocytic leukemia (CMML) is a rare and aggressive hematologic malignancy characterized by features of both myelodysplastic syndromes and myeloproliferative neoplasms. CMML primarily affects older adults and is associated with poor clinical outcomes, including progressive bone marrow failure and risk of transformation to acute myeloid leukemia (AML). Current treatment options remain limited, highlighting the need for novel targeted therapies that can improve outcomes for patients with this disease.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Cardiff Oncology’s expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate; results of preclinical studies or clinical trials for our product candidate could be unfavorable or delayed; our need for additional financing; risks related to business interruptions, including cyber-attacks on our information technology infrastructure, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that our product candidate will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology’s Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Investor Contact:
Candice Masse
astr partners
[email protected]

Media Contact:
Amy Bonanno
Lyra Strategic Advisory
[email protected]

Release – SKYX and Its Subsidiary Deako Announce They Will Supply Over 80,000 Units of Their Smart Home Technologies to Over 1,000 Homes of Prominent Home Builder Maronda Homes, as the Company Continues to Grow Its Market Penetration

Posted on by [email protected]

MIAMI, Oct. 21, 2026 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (the “Company” or “SKYX”), a highly disruptive platform technology company with over 120 patents and pending applications globally and over 60 lighting and home décor websites, with a mission to make homes and buildings become safe and smart as the new standard, today announced that it will supply over 80,000 units of its advanced technologies to over 1,000 homes of prominent community and home builder Maronda Homes as it continues to grow its market penetration

Maronda Homes is a private, family-owned home builder founded in 1972 by William J. Wolf. Maronda has built over 70,000 homes across the United States and is currently building homes and communities across Florida, Ohio, Georgia, Alabama, Indiana, Kentucky, Maryland, Pennsylvania, South Carolina, Virginia, and West Virginia.

As a community and home builder many of Maronda Homes communities include resort-style pools and clubhouses to fitness centers, pickleball courts, dog parks, walking trails and playgrounds. Maronda communities are designed to bring families together.

The Company expects to deliver over 80,000 units of its advanced plug-and-play and smart home technologies to over 1,000 Maronda Homes residences in several states including Ohio, Georgia, Maryland, and Pennsylvania.

Maronda Homes offers a Certified Energy Efficient package designed to pair everyday comfort with smart home technology. Electrical and smart home package features may vary by market, community, and home.

For information about Maronda Homes, click here: www.marondahomes.com

For more information about SKYX and Deako, go to www.SKYX.com and www.Deako.com

Derek Richardson, Founder and CEO of Deako, stated: “This program with Maronda is a natural next step for Deako. Every new Maronda home in these communities starts with a smart home foundation that is simple for the builder to deliver and easy for the homeowner to grow. Pairing that package with the communities Maronda builds, from resort-style pools to walking trails, is the kind of home people are looking for, and it gives us a model we can repeat with builders across the country.”

Rani Kohen, Founder and Executive Chairman of SKYX Platforms, said: “We are very pleased to be working with such a prominent home builder, Maronda Homes. We expect to keep expanding our builder programs with our subsidiary Deako and look forward to continuing to grow our market penetration while creating safer, more advanced, and smarter homes and buildings of the future.”

About SKYX Platforms Corp.

As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced, safe, smart and AI platform technologies, with over 120 U.S. and global patents and patent pending applications. Additionally, the Company owns 60 lighting and home décor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://www.skyx.com/ or follow us on LinkedIn.

Forward-Looking Statements

Certain statements made in this press release are not based on historical facts, but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “can,” “could,” “continue,” “estimate,” “expect,” “evaluate,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “target” “view,” “will,” or “would,” or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company’s reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to the Company’s ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with third-party platforms or technologies; the Company’s ability to achieve positive cash flows; the Company’s efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company’s ability to capture market share; the Company’s estimates of its potential addressable market and demand for its products and technologies; the Company’s ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company’s ability to continue as a going concern; the Company’s ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company’s products will become National Electrical Code (NEC)-code or otherwise code mandatory in any jurisdiction, or that any of the Company’s current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company’s ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company’s actual operating results; the potential impact of unstable market and economic conditions on the Company’s business, financial condition, and stock price; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws.

Investor Relations Contacts:

Jeff Ramson
PCG Advisory
[email protected]

Ronald A. Both
Encore Investor Relations
[email protected]

Cencora to Acquire American Oncology Network for $2.4 Billion in Major Cancer Care Expansion

Posted on by [email protected]

Cencora (NYSE: COR) has announced an agreement to acquire American Oncology Network (OTCQX: AONC) in a transaction valued at up to $2.4 billion, expanding the pharmaceutical distribution giant’s presence in community-based cancer care. The deal, announced October 21, 2026, will add a physician-led network of more than 350 oncology providers operating across 21 states to Cencora’s growing healthcare services platform.

The acquisition represents another significant step in Cencora’s strategy to expand beyond traditional pharmaceutical distribution and strengthen its relationships with healthcare providers. By integrating American Oncology Network’s clinical infrastructure and practice management capabilities, Cencora aims to support independent cancer specialists while improving patient access to advanced treatments.

Under the agreement, American Oncology Network is valued at $2.3 billion at closing, with an additional $100 million potentially payable through contingent value rights tied to specified conditions. Cencora already owns approximately 4% of the company and has agreed to acquire the remaining equity interests, subject to a potential ownership rollover by existing shareholders.

If eligible shareholders retain a combined 25% stake, Cencora expects to pay approximately $1.7 billion at closing to increase its ownership to 75%. The transaction remains subject to regulatory approvals, shareholder approval, and customary closing conditions.

Founded in 2018, American Oncology Network provides operational and administrative support to independent oncology practices, allowing physicians to concentrate on patient care. Its services include practice management, technology, and access to integrated healthcare resources designed to help smaller cancer treatment centers compete in an increasingly complex healthcare environment.

For Cencora, the acquisition expands its physician-led oncology management services organization into 12 additional states. The company expects the combination to create opportunities to strengthen cancer treatment delivery, expand practice support capabilities, and improve operational efficiency.

The transaction also highlights the growing importance of community oncology as cancer treatments become increasingly specialized and expensive. Independent oncology practices face mounting challenges involving reimbursement, drug procurement, technology investment, and administrative costs. Larger healthcare organizations are responding by building networks that provide centralized resources while allowing physicians to retain control over clinical decisions.

The expansion comes as biotechnology companies continue developing innovative cancer treatments that could eventually reach patients through community oncology practices. Companies such as Greenwich LifeSciences (NASDAQ: GLSI), which is developing an investigational immunotherapy for breast cancer, and MAIA Biotechnology (NYSE American: MAIA), which is advancing a telomere-targeting cancer treatment, illustrate the broader pipeline of emerging oncology therapies. Neither company is involved in the announced transaction.

For investors, the deal underscores how pharmaceutical distribution companies are seeking additional growth opportunities in specialized healthcare services. Expanding into oncology practice management could provide Cencora with deeper relationships across the cancer treatment market while supporting demand for pharmaceutical products and services.

Cencora expects the acquisition to contribute positively to adjusted diluted earnings per share beginning in the second year following completion. The company also raised its fiscal 2026 adjusted earnings outlook to at least $17.90 per share, reflecting strength in its U.S. Healthcare Solutions business.

The acquisition illustrates a broader shift toward integrated cancer care, where pharmaceutical distribution, clinical services, and healthcare technology increasingly operate within connected networks. As cancer treatments continue evolving, companies capable of supporting both drug delivery and community-based medical practices could play a larger role in shaping the future of oncology care.

NetSol Technologies, Inc. (NTWK) – Transcending to the Next Stage of Growth

Posted on by [email protected]


Wednesday, October 21, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating coverage. We are initiating coverage of NetSol Technologies, a global provider of lending, leasing, and digital retail software to auto captives, banks, and equipment lenders. In our view, NetSol’s long-standing customer relationships and Transcend platform position it to benefit as lenders replace aging systems and to shift more revenue from one-time licenses to recurring subscriptions.

A record year. Fiscal 2026 revenue rose 12.5% to a record $74.4 million. Recurring subscription and support revenue grew 8.7% to $35.8 million and accounts for nearly half of total revenue. We believe the increased adoption of the Transcend platform’s subscription model should improve revenue visibility and reduce reliance on individual contract wins.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

FreightCar America (RAIL) – Outlook Reset Following Tank Car Retrofit Order Removal

Posted on by [email protected]


Wednesday, October 21, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Tank car retrofit order removed from backlog. FreightCar America removed 1,285 railcars associated with a tank car retrofit contract from its backlog after determining that the customer was unlikely to fulfill its contractual obligations. The order included deliveries scheduled for the second half of 2026 and throughout 2027. Management emphasized that the cancellation is specific to one customer and does not affect other orders. Following the adjustment, the September 30, 2026, backlog totaled 2,660 railcars valued at $284.5 million.

Preliminary Q3 2026 results reflect lower production volumes. FreightCar America expects third-quarter revenue of $75 million to $77 million, down approximately 53% from $160.5 million in the prior-year period. Railcar deliveries declined 49% to 662 units, while adjusted EBITDA is expected to be approximately breakeven, compared with $17.0 million a year earlier. We now forecast revenue of $76.1 million, adjusted EBITDA of $0.0 million, and a loss of $(0.13) per share.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Lycia Therapeutics Targets $250 Million IPO as Biotech Market Rebounds

Posted on by [email protected]

Lycia Therapeutics is preparing to raise approximately $250 million through an initial public offering, becoming the latest biotechnology company seeking to capitalize on renewed investor interest in emerging drug developers. The South San Francisco-based company announced plans Tuesday to offer 14.7 million shares priced between $16 and $18 each, potentially valuing the business at approximately $950 million on a fully diluted basis.

The company intends to list on the Nasdaq under the ticker symbol LYCA, adding another early-stage biotechnology developer to a growing pipeline of healthcare IPOs. The offering comes as investors increasingly look beyond established pharmaceutical companies toward emerging businesses developing innovative treatments for diseases with significant unmet medical needs.

Lycia is developing a new class of medicines designed to eliminate disease-causing proteins from the body. Its proprietary LYTAC technology, short for Lysosomal Targeting Chimera, works by directing specific proteins toward the body’s natural cellular disposal system. Unlike traditional drugs that primarily block the activity of harmful proteins, Lycia’s approach aims to remove them altogether.

The technology is based on research associated with Nobel Prize-winning chemist Carolyn Bertozzi, who helped establish the company in 2019. Lycia is initially targeting autoimmune, inflammatory, and allergic diseases, areas where conventional treatments often require ongoing symptom management.

Its lead experimental treatment, LCA-0061, is being developed for food allergies and other allergic conditions. The therapy targets immunoglobulin E, or IgE, an antibody responsible for triggering many allergic reactions. Early Phase 1 results showed a mean maximum IgE reduction of 96% from baseline among treated participants in an initial small cohort, although larger studies will be needed to determine its safety and effectiveness in patients.

Lycia is also developing LCA-0321, an experimental treatment for Graves’ disease, an autoimmune condition affecting the thyroid. The candidate is designed to selectively eliminate disease-causing antibodies rather than broadly suppress the immune system.

Lycia’s focus on targeted therapies for autoimmune and inflammatory conditions also reflects broader innovation across the biotechnology sector. Eledon Pharmaceuticals (NASDAQ: ELDN) is developing tegoprubart, an investigational treatment designed to regulate immune system activity by targeting the CD40 ligand pathway, with applications in organ transplantation. Meanwhile, Gyre Therapeutics (NASDAQ: GYRE) is focused on developing treatments for inflammatory and fibrotic diseases, including liver-related conditions. Although these companies employ different scientific approaches, their development programs highlight growing interest in therapies that address specific biological mechanisms underlying complex diseases.

Proceeds from the IPO are expected to support clinical development of these programs, additional research activities, and general corporate operations. The company has already raised approximately $267 million from private investors, including several prominent life sciences investment firms.

The planned offering follows a series of biotechnology IPOs that suggest improving conditions for companies seeking public-market financing. City Therapeutics and Iambic Therapeutics recently completed offerings that raised approximately $350 million combined, highlighting investor interest in RNA-based medicines and artificial intelligence-driven drug discovery.

While these companies are pursuing different technologies, their emergence reflects a broader shift toward specialized drug development platforms that could generate multiple treatments across different diseases.

For investors, Lycia’s proposed IPO offers exposure to an emerging area of biotechnology known as targeted protein degradation. The technology could eventually expand treatment possibilities for diseases where existing therapies have limited effectiveness, although its clinical and commercial potential remains unproven.

The offering also carries substantial risks. Lycia remains an early-stage clinical developer without an approved commercial product, and its future valuation will depend heavily on clinical trial results, regulatory progress, and its ability to finance continued research.

As more biotechnology companies test public-market demand, Lycia’s offering could provide another indication of whether investor appetite for early-stage drug developers is strengthening heading into the final months of 2026.

Release – Conduent Teams with New Jersey to Roll Out Chip-Enabled SNAP Cards to Prevent EBT Theft

Posted on by [email protected]

October 20, 2026

Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services company, today announced its collaboration with the New Jersey Department of Human Services to provide people in need across the state with chip-enabled EBT cards designed to prevent benefit theft and protect their funds. The new cards, which are available to clients of the Supplemental Nutrition Assistance Program (SNAP) and the Work First New Jersey (WFNJ) cash assistance program, also allow for tap-to-pay functionality – making it the first Conduent-supported state to include this capability.

“We are excited to make these more secure cards available to all residents who participate in SNAP or the WFNJ program. The chip-enabled cards provide an added layer of security and are an important tool in our ongoing efforts to safeguard benefits and protect residents who rely on this assistance from this type of widespread benefit fraud,” said New Jersey Human Services Commissioner Stephen Cha.

EBT cards for SNAP and other benefits have traditionally relied on magnetic stripes that are vulnerable to skimming, where criminals install devices on point-of-sale terminals or ATMs to steal card information. With chips, New Jersey cardholders can now insert their cards into the terminals rather than swiping them, adding a critical layer of protection.

Beneficiaries in New Jersey can also use their EBT cards to access benefits using tap-to-pay functionality. This means cardholders can simply tap their cards at enabled terminals, reducing the risk of benefit theft while improving speed and ease of use.

Cardholders should continue to lock their card when not in use. New Jersey EBT cards can be locked and unlocked at NJFamiliesFirst.gov or by using the ConnectEBT app, which is available in Apple App Store or Google Play Store. In addition to engaging card lock features, cardholders should always maintain the privacy of their four-digit personal identification number (PIN) and identifying card information.

“As thieves increasingly have targeted taxpayer-funded government benefits in recent years, chip-enabled payment technology has emerged as a key tool to reduce EBT theft, improve account security and ensure critical funds go to rightful recipients,” said Anna Sever, President, Government Solutions at Conduent. “Conduent is proud to help states deploy this technology that also offers more flexible, fast and convenient payment options, such as tap-to-pay.”

Aside from New Jersey, Conduent continues to work with several other states that have transitioned, or are in the process of transitioning, to chip-enabled cards. Earlier this year, the company announced a collaboration with Alabama to become the second state to roll out chipped EBT cards to all its beneficiaries statewide.

The chip-enabled technology is among Conduent’s VeriSight Anti-Fraud Solutions , a suite of innovative offerings that help agencies address fraud and theft risks in public benefit programs. The suite also includes the lock and unlock capabilities with ConnectEBT, plus adaptive theft detection tools for EBT customer service centers that can identify and block suspicious activity, such as unusual phone numbers or high call volumes.

Conduent is a national leader in government payment disbursements, having disbursed approximately $80 billion in government benefit payments in 2025. Conduent also supports U.S. government agencies with end-to-end solutions for healthcare claims processing, eligibility and enrollment, and child support administration.

About Conduent

Conduent is a global technology-enabled operating partner that helps businesses and governments simplify complexity, modernize mission-critical operations and deliver measurable outcomes through AI, automation, data and human expertise. Learn more at www.conduent.com .

Note: To receive RSS news feeds, visit www.news.conduent.com . For open commentary, industry perspectives and views, visit https://x.com/Conduent , http://www.linkedin.com/company/Conduent or http://www.facebook.com/Conduent .

Trademarks

Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

Media Contact:
Neil Franz, Conduent, [email protected] , +1-240-687-0127

Investor Relations Contact:
Nick Goel, Conduent, [email protected]